# Stifel Financial Corp: financial statements, quarterly

SF · NYSE · CIK 720672 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sf.md) · [Financials](/companies/sf/financials.md) · [Filings](/companies/sf/filings.md) · [Insiders](/companies/sf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [646](/filings/0000950170-24-121838.md) | [711 d](/filings/0000950170-25-027702.md) | [768](/filings/0000950170-25-065599.md) | [799](/filings/0000950170-25-103991.md) | [811](/filings/0001193125-25-266891.md) | [916 d](/filings/0001193125-26-067130.md) | [842](/filings/0001193125-26-202795.md) | [839](/filings/0001193125-26-333953.md) | [963](/filings/0001193125-25-266891.md) | [1,127 d](/filings/0001193125-26-067130.md) | [1,010](/filings/0001193125-26-202795.md) | [1,012](/filings/0001193125-26-333953.md) |
| Interest expense | $m | [221](/filings/0000950170-24-121838.md) | [244 d](/filings/0001193125-26-067130.md) | [255](/filings/0000950170-25-065599.md) | [247](/filings/0000950170-25-103991.md) | [251](/filings/0001193125-25-266891.md) | [228 d](/filings/0001193125-26-067130.md) | [214](/filings/0001193125-26-202795.md) | [207](/filings/0001193125-26-333953.md) | [205](/filings/0001193125-25-266891.md) | [192 d](/filings/0001193125-26-067130.md) | [187](/filings/0001193125-26-202795.md) | [188](/filings/0001193125-26-333953.md) |
| Income tax | $m | [41.3](/filings/0000950170-24-121838.md) | [43.5 d](/filings/0001193125-26-067130.md) | [55.1](/filings/0000950170-25-065599.md) | [61.6](/filings/0000950170-25-103991.md) | [58.2](/filings/0001193125-25-266891.md) | [22.2 d](/filings/0001193125-26-067130.md) | [10.4](/filings/0001193125-26-202795.md) | [58.8](/filings/0001193125-26-333953.md) | [74.7](/filings/0001193125-25-266891.md) | [43.5 d](/filings/0001193125-26-067130.md) | [74.7](/filings/0001193125-26-202795.md) | [73.0](/filings/0001193125-26-333953.md) |
| Net income | $m | [68.2](/filings/0000950170-24-121838.md) | [162 d](/filings/0001193125-26-067130.md) | [164](/filings/0000950170-25-065599.md) | [165](/filings/0000950170-25-103991.md) | [159](/filings/0001193125-25-266891.md) | [244 d](/filings/0001193125-26-067130.md) | [53.0](/filings/0001193125-26-202795.md) | [155](/filings/0001193125-26-333953.md) | [211](/filings/0001193125-25-266891.md) | [264 d](/filings/0001193125-26-067130.md) | [251](/filings/0001193125-26-202795.md) | [226](/filings/0001193125-26-333953.md) |
| Diluted EPS | $ per share | [0.52](/filings/0000950170-24-121838.md) | not reported | [1.40](/filings/0000950170-25-065599.md) | [1.41](/filings/0000950170-25-103991.md) | [1.34](/filings/0001193125-25-266891.md) | not reported | [0.26](/filings/0001193125-26-202795.md) | [0.89](/filings/0001193125-26-333953.md) | [1.84](/filings/0001193125-25-266891.md) | not reported | [1.48](/filings/0001193125-26-202795.md) | [1.34](/filings/0001193125-26-333953.md) |
| Basic EPS | $ per share | [0.55](/filings/0000950170-24-121838.md) | not reported | [1.48](/filings/0000950170-25-065599.md) | [1.50](/filings/0000950170-25-103991.md) | [1.43](/filings/0001193125-25-266891.md) | not reported | [0.28](/filings/0001193125-26-202795.md) | [0.94](/filings/0001193125-26-333953.md) | [1.96](/filings/0001193125-25-266891.md) | not reported | [1.56](/filings/0001193125-26-202795.md) | [1.41](/filings/0001193125-26-333953.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.8](/filings/0000950170-23-060302.md) | [3.4](/filings/0001193125-26-067130.md) | [3.4](/filings/0000950170-24-055125.md) | [2.6](/filings/0000950170-24-092303.md) | [1.9](/filings/0000950170-24-121838.md) | [2.6](/filings/0001193125-26-067130.md) | [2.7](/filings/0000950170-25-065599.md) | [1.9](/filings/0000950170-25-103991.md) | [3.2](/filings/0001193125-25-266891.md) | [2.3](/filings/0001193125-26-333953.md) | [2.9](/filings/0001193125-26-202795.md) | [2.2](/filings/0001193125-26-333953.md) |
| Total assets | $bn | [37.9](/filings/0000950170-23-060302.md) | [37.7](/filings/0000950170-25-027702.md) | [38.3](/filings/0000950170-24-055125.md) | [37.8](/filings/0000950170-24-092303.md) | [38.9](/filings/0000950170-24-121838.md) | [39.9](/filings/0001193125-26-067130.md) | [40.4](/filings/0000950170-25-065599.md) | [39.9](/filings/0000950170-25-103991.md) | [41.7](/filings/0001193125-25-266891.md) | [41.3](/filings/0001193125-26-333953.md) | [42.9](/filings/0001193125-26-202795.md) | [44.9](/filings/0001193125-26-333953.md) |
| Total liabilities | $bn | [32.6](/filings/0000950170-23-060302.md) | [32.4](/filings/0000950170-25-027702.md) | [33.0](/filings/0000950170-24-055125.md) | [32.4](/filings/0000950170-24-092303.md) | [33.4](/filings/0000950170-24-121838.md) | [34.2](/filings/0001193125-26-067130.md) | [34.8](/filings/0000950170-25-065599.md) | [34.3](/filings/0000950170-25-103991.md) | [35.9](/filings/0001193125-25-266891.md) | [35.3](/filings/0001193125-26-333953.md) | [36.9](/filings/0001193125-26-202795.md) | [38.9](/filings/0001193125-26-333953.md) |
| Long-term debt | $bn | [1.1](/filings/0000950170-23-060302.md) | [1.1](/filings/0000950170-25-027702.md) | [1.1](/filings/0000950170-24-055125.md) | [1.1](/filings/0000950170-24-092303.md) | [0.6](/filings/0000950170-24-121838.md) | [0.6](/filings/0001193125-26-067130.md) | [0.6](/filings/0000950170-25-065599.md) | [0.6](/filings/0000950170-25-103991.md) | [0.6](/filings/0001193125-25-266891.md) | [0.6](/filings/0001193125-26-333953.md) | [0.6](/filings/0001193125-26-202795.md) | [0.6](/filings/0001193125-26-333953.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [5.2](/filings/0000950170-24-121838.md) | [5.3](/filings/0001193125-26-067130.md) | [5.3](/filings/0000950170-25-065599.md) | [5.4](/filings/0000950170-25-103991.md) | [5.6](/filings/0001193125-25-266891.md) | [5.7](/filings/0001193125-26-067130.md) | [5.5](/filings/0001193125-26-202795.md) | [5.6](/filings/0001193125-26-333953.md) | [5.8](/filings/0001193125-25-266891.md) | [6.0](/filings/0001193125-26-333953.md) | [6.0](/filings/0001193125-26-202795.md) | [6.0](/filings/0001193125-26-333953.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [230 d](/filings/0000950170-24-121838.md) | [275 d](/filings/0001193125-26-067130.md) | [(610)](/filings/0000950170-25-065599.md) | [477 d](/filings/0000950170-25-103991.md) | [199 d](/filings/0001193125-25-266891.md) | [424 d](/filings/0001193125-26-067130.md) | [(211)](/filings/0001193125-26-202795.md) | [607 d](/filings/0001193125-26-333953.md) | [338 d](/filings/0001193125-25-266891.md) | [382 d](/filings/0001193125-26-067130.md) | [(343)](/filings/0001193125-26-202795.md) | [76.1 d](/filings/0001193125-26-333953.md) |
| Capital expenditure | $m | [12.3 d](/filings/0000950170-24-121838.md) | [13.0 d](/filings/0001193125-26-067130.md) | [9.6](/filings/0000950170-25-065599.md) | [34.0 d](/filings/0000950170-25-103991.md) | [12.8 d](/filings/0001193125-25-266891.md) | [17.4 d](/filings/0001193125-26-067130.md) | [16.6](/filings/0001193125-26-202795.md) | [14.8 d](/filings/0001193125-26-333953.md) | [17.2 d](/filings/0001193125-25-266891.md) | [13.5 d](/filings/0001193125-26-067130.md) | [47.8](/filings/0001193125-26-202795.md) | [14.8 d](/filings/0001193125-26-333953.md) |
| Share repurchases | $m | [119 d](/filings/0000950170-24-121838.md) | [144 d](/filings/0001193125-26-067130.md) | [60.7](/filings/0000950170-25-065599.md) | [17.6 d](/filings/0000950170-25-103991.md) | [20.2 d](/filings/0001193125-25-266891.md) | [45.6 d](/filings/0001193125-26-067130.md) | [93.2](/filings/0001193125-26-202795.md) | [83.0 d](/filings/0001193125-26-333953.md) | [31.2 d](/filings/0001193125-25-266891.md) | [37.5 d](/filings/0001193125-26-067130.md) | [96.4](/filings/0001193125-26-202795.md) | [172 d](/filings/0001193125-26-333953.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [117](/filings/0000950170-23-060302.md) | [115](/filings/0000950170-24-055125.md) | [114](/filings/0000950170-24-092303.md) | [113](/filings/0000950170-24-121838.md) | [110](/filings/0000950170-25-065599.md) | [110](/filings/0000950170-25-103991.md) | [111](/filings/0001193125-25-266891.md) | [166](/filings/0001193125-26-202795.md) | [163](/filings/0001193125-26-333953.md) | [110](/filings/0001193125-25-266891.md) | [163](/filings/0001193125-26-202795.md) | [162](/filings/0001193125-26-333953.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 69,584,449 at 2019-08-01, from the cover of the [10-Q filed 2019-08-07](/filings/0001564590-19-029678.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.